Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Finance

25 January 2024

GenSight Biologics Reports Cash Position as of December 31, 2023, and Provides Business Update

27 December 2023

GenSight Biologics Provides Business and Financial Update

22 November 2023

GenSight Biologics announces the availability of a prospectus in connection with the listing of new shares on Euronext Paris

21 November 2023

GenSight Biologics announces a successful offering for an amount of approximately €4.7 million

20 November 2023

GenSight Biologics announces launch of an offering for an indicative amount of €5 million that has received subscription commitments from new and existing shareholders totaling €4 million

26 October 2023

GenSight Biologics Reports Cash Position as of September 30, 2023, and Provides Business Update

15 September 2023

GenSight Biologics Reports Interim Financial Results for the First Half of 2023

03 August 2023

GenSight Biologics obtains funding of €10 million from Sofinnova Partners, Invus and UPMC Enterprises

20 July 2023

GenSight Biologics Provides Financial and Operational Update

31 May 2023

Annual General Meeting on June 21, 2023

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 12
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page